The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 4, 2007, Pages 503-509

  Friedman, E A ^a   Harris, P A ^a   Wood, A J J ^a   Stein, C M ^a   Kurnik, D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; TADALAFIL;

ADULT; ARTICLE; BLOOD FLOW; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; COLD EXPOSURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; HEART PALPITATION; HUMAN; HYPOTENSION; ISCHEMIA; LASER DOPPLER FLOWMETRY; MALE; MULTIPLE CYCLE TREATMENT; NOSE CONGESTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; REST; SINGLE DRUG DOSE; TEMPERATURE SENSITIVITY; THERMAL EXPOSURE; VASOCONSTRICTION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADULT; CARBOLINES; COLD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; RAYNAUD DISEASE; REGIONAL BLOOD FLOW; SKIN; SKIN TEMPERATURE; VASOCONSTRICTION;

EID: 33947364879     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100103     Document Type: Article

References (32)

1. Suter, L.G., Murabito, J.M., Felson, D.T. & Fraenkel, L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 52, 1259-1263 (2005).
2. Flavahan, N.A., Flavahan, S., Mitra, S. & Chotani, M.A. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 29, 275-291 (2003) vi.
3. Ignarro, L.J., Cirino, G., Casini, A. & Napoli, C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 34, 879-886 (1999).
4. Leppert, J., Ringqvist, A., Ahlner, J., Myrdal, U., Sorensen, S. & Ringqvist, I. Cold exposure increases cyclic guanosine monophosphate in healthy women but not in women with Raynaud's phenomenon. J Intern Med 237, 493-498 (1995).
5. Ringqvist, A., Jonason, T., Leppert, J. & Ringqvist, I. Non-invasive investigation of endothelium-dependent dilatation of the brachial artery in women with primary Raynaud's phenomenon. Clin Sci (London) 94, 239-243 (1998).
6. Bedarida, G., Kim, D., Blaschke, T.F. & Hoffman, B.B. Venodilation in Raynaud's disease. Lancet 342, 1451-1454 (1993).
7. Gardner-Medwin, J.M., Macdonald, I.A., Taylor, J.Y., Riley, P.H. & Powell, R.J. Seasonal differences in finger skin temperature and microvascular blood flow in healthy men and women are exaggerated in women with primary Raynaud's phenomenon. Br J Clin Pharmacol 52, 17-23 (2001).
8. Freedman, R.R., Girgis, R. & Mayes, M.D. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. J Rheumatol 26, 2386-2388 (1999).
9. Baumhaekel, M., Scheffler, P. & Boehm, M. Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. Microvasc Res 69, 178-179 (2005).
10. Rosenkranz, S. et al. Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome. Dtsch Med Wochenschr 129, 1736-1740 (2004).
11. Kumana, C.R., Cheung, G.T. & Lau, C.S. Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis 63, 1522-1524 (2004).
12. Colglazier, C.L., Sutej, P.G. & O'Rourke, K.S. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J Rheumatol 32, 2440-2442 (2005).
13. Gore, J. & Silver, R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 64, 1387 (2005).
14. Lichtenstein, J.R. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al. Arthritis Rheum 48, 282-283 (2003).
15. Fries, R., Shariat, K., von Wilmowsky, H. & Bohm, M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112, 2980-2985 (2005).
16. Caglayan, E. et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 166, 231-233 (2006).
17. Kukreja, R.C. et al. Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul Pharmacol 42, 219-232 (2005).
18. Khan, F. & Belch, J.J. Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation. J Rheumatol 26, 2389-2394 (1999).
19. Charkoudian, N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc 78, 603-612 (2003).
20. Thomas, G.D. & Victor, R.G. Nitric oxide mediates contraction-induced attenuation of sympathetic vasoconstriction in rat skeletal muscle. J Physiol 506(Part 3): 817-826 (1998).
21. Khan, F., Palacino, J.J., Coffman, J.D. & Cohen, R.A. Chronic inhibition of nitric oxide production augments skin vasoconstriction in the rabbit ear. J Cardiovasc Pharmacol 22, 280-286 (1993).
22. Park, J.W., Mrowietz, C., Chung, N. & Jung, F. Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study. Clin Hemorheol Microcirc 31, 173-183 (2004).
23. Cialis (tadalafil) Product Label Information, revised version (05/17/ 2006) http://www.fda.gov/cder/foi/label/2005/021368s00405lbl.pdf last accessed June 14, 2006. 5-17-2006.
24. Seal, J.B. & Gewertz, B.L. Vascular dysfunction in ischemia-reperfusion injury. Ann Vasc Surg 19, 572-584 (2005).
25. Halcox, J.P. et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 40, 1232-1240 (2002).
26. Berkels, R., Klotz, T., Sticht, G., Englemann, U. & Klaus, W. Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. J Cardiovasc Pharmacol 37, 413-421 (2001).
27. Hirata, K., Adji, A., Vlachopoulos, C. & O'Rourke, M.F. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 96, 1436-1440 (2005).
28. Kleinsasser, A. et al. Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med 163, 339-343 (2001).
29. Maricq, H.R. & Weinrich, M.C. Diagnosis of Raynaud's phenomenon assisted by color charts. J Rheumatol 15, 454-459 (1988).
30. Bartelink, M.L., Wollersheim, H., Theeuwes, A., van Duren, D. & Thien, T. Changes in skin blood flow during the menstrual cycle: the influence of the menstrual cycle on the peripheral circulation in healthy female volunteers. Clin Sci (London) 78, 527-532 (1990).
31. Berardesca, E., Leveque, J.L. & Masson, P. EEMCO guidance for the measurement of skin microcirculation. Skin Pharmacol Appl Skin Physiol 15, 442-456 (2002).
32. Kellogg, D.L. Jr, Liu, Y., Kosiba, I.F. & O'Donnell, D. Role of nitric oxide in the vascular effects of local warming of the skin in humans. J Appl Physiol 86, 1185-1190 (1999).